ZIOP ZIOPHARM Oncology Inc

4.36
+0.07  (+2%)
Previous Close 4.29
Open 4.31
Price To Book 9.48
Market Cap 708039994
Shares 162,394,494
Volume 959,737
Short Ratio
Av. Daily Volume 1,687,912

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 pivotal trial plans on hold due to Chemistry and Manufacturing Control (CMC) issues.
Ad-RTS-hIL-12 + veledimex
Glioblastoma multiforme (GBM)
Phase 1 initial data due at ASCO June 2, 2019, 8am.
Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO (nivolumab)
Refractory glioblastoma multiforme (GBM)
Phase 1 ongoing.
Ad-RTS-hIL-12 + veledimex
Brain cancer
Phase 1 ongoing.
CD33-specific CAR+ T
Acute Myeloid Leukemia (AML)
Phase 1 trial to begin dosing mid-2019.
Sleeping beauty - TCR-T cell therapy
Solid tumors
Phase 1 data due at ASCO June 2, 2019, 8am.
Ad-RTS-hIL-12
recurrent glioblastoma (rGBM)
Phase 2 trial to commence 2Q 2019.
Ad-RTS-hIL-12 plus veledimex plus Libtayo
Refractory glioblastoma multiforme (GBM)

Latest News

  1. Edited Transcript of ZIOP earnings conference call or presentation 8-May-19 8:30pm GMT
  2. Ziopharm: 1Q Earnings Snapshot
  3. Ziopharm Oncology Reports First Quarter 2019 Financial Results and Reaffirms Clinical Timelines
  4. ZIOPHARM Oncology, Inc. to Host Earnings Call
  5. Ziopharm Oncology to Host Conference Call to Discuss First Quarter 2019 Financial Results on May 8, 2019
  6. Edited Transcript of ZIOP earnings conference call or presentation 5-Mar-19 9:30pm GMT
  7. What Kind Of Shareholder Appears On The ZIOPHARM Oncology, Inc.'s (NASDAQ:ZIOP) Shareholder Register?
  8. Ziopharma's Lead Asset Snags Fast Track Designation For Cancer Treatment
  9. Ziopharm Oncology Announces FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Recurrent Glioblastoma
  10. Ziopharm Oncology Inc (ZIOP) Q4 2018 Earnings Conference Call Transcript
  11. Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  12. Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4
  13. Ziopharm Oncology to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 5
  14. Ziopharm Oncology CEO to Present at the CAR-TCR Summit Europe
  15. Recent Analysis Shows Lattice Semiconductor, ZIOPHARM Oncology, Ferro, SYNNEX, AxoGen, and Twin Disc Market Influences — Renewed Outlook, Key Drivers of Growth
  16. Is ZIOPHARM Oncology, Inc.’s (NASDAQ:ZIOP) CEO Paid At A Competitive Rate?
  17. Ziopharm Oncology Completes Enrollment of Controlled IL-12 Monotherapy Expansion Substudy in Phase 1 Brain Cancer Trial
  18. The Unknown Biotech Play that Could Deliver 400% Returns, or Much More
  19. Biotech Stocks on the Move
  20. Ziopharm Oncology Posts Letter to Stockholders